AU2612100A - Methods of promoting or enhancing interleukin-12 production through administration of thalidomide - Google Patents

Methods of promoting or enhancing interleukin-12 production through administration of thalidomide

Info

Publication number
AU2612100A
AU2612100A AU26121/00A AU2612100A AU2612100A AU 2612100 A AU2612100 A AU 2612100A AU 26121/00 A AU26121/00 A AU 26121/00A AU 2612100 A AU2612100 A AU 2612100A AU 2612100 A AU2612100 A AU 2612100A
Authority
AU
Australia
Prior art keywords
thalidomide
promoting
administration
production
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26121/00A
Other languages
English (en)
Inventor
Patrick A. J. Haslett
Gilla Kaplan
Stephen J. Oliver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of AU2612100A publication Critical patent/AU2612100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU26121/00A 1999-01-13 2000-01-13 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide Abandoned AU2612100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22921899A 1999-01-13 1999-01-13
US09229218 1999-01-13
PCT/US2000/000914 WO2000041547A2 (fr) 1999-01-13 2000-01-13 Procedes permettant de favoriser ou de renforcer la production d'interleukine-12 par administration de thalidomide

Publications (1)

Publication Number Publication Date
AU2612100A true AU2612100A (en) 2000-08-01

Family

ID=22860287

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26121/00A Abandoned AU2612100A (en) 1999-01-13 2000-01-13 Methods of promoting or enhancing interleukin-12 production through administration of thalidomide

Country Status (2)

Country Link
AU (1) AU2612100A (fr)
WO (1) WO2000041547A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212826D0 (en) * 2002-05-31 2002-07-10 Dna Res Innovations Ltd Materials and methods relating to polyions and substance delivery
NZ550026A (en) * 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (fr) * 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
WO1998022137A1 (fr) * 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION DU FNTα ET DE IL-12 EN THERAPIE

Also Published As

Publication number Publication date
WO2000041547A2 (fr) 2000-07-20
WO2000041547A3 (fr) 2000-11-30

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU1177601A (en) Block toy
IL149907A0 (en) Nutritional composition, methods of producing said composition and methods of using said composition
AU1267400A (en) Pharmaceutical moxifloxacin preparation
AU9226798A (en) Infant sleeper
AU1101699A (en) Therapeutic pillow
PL351686A1 (en) Novel pharmaceutical
AU715620C (en) Therapeutic methods and uses
AU1409100A (en) Drugs
EG23937A (en) Novel pharmaceutical
AU7332800A (en) Card construction, methods of making and using
AU3467099A (en) Methods for production of therapeutic cytokines
AU7445100A (en) Sebum production inhibitors
PL354994A1 (en) Bio-supportive matrices, methods of making and using the same
HUP0201667A2 (en) Oral form of administration
PL351135A1 (en) Novel pharmaceutical
HUP0401622A3 (en) Gelling sugar and method for producing the same
EG23946A (en) Novel pharmaceutical
AU5448300A (en) Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
AU2612100A (en) Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
AU1688099A (en) Pharmaceutical preparation
HUP0203443A3 (en) Novel contraceptive medicament and method for producing the same
AU6194899A (en) Pharmaceutical preparation containing taxane and method for producing the same
AU2279800A (en) Pharmaceutical preparation
AU1991300A (en) Gemstone setting

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase